Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Pharmaceuticals

Market Closed - NSE India S.E. 08:01:59 2024-03-28 am EDT 5-day change 1st Jan Change
984.8 INR +0.01% Intraday chart for Alembic Pharmaceuticals Limited +4.16% +29.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alembic Pharmaceuticals Limited Receives Order from Commission of Customs, Mumbai Zone- III CI
Alembic Pharmaceuticals' Oncology Plant in Gujarat, India Gets One Observation from US FDA MT
Alembic Pharmaceuticals Limited Announces United States Food and Drug Administration Conducted an Inspection At Oncology Formulation Facility At Panelav CI
Crisil Keeps AA+ Rating on Alembic Pharmaceuticals' Bank Loans with Stable Outlook MT
Indian shares seen muted tracking broader Asian equities RE
Alembic Pharmaceuticals Fully Resumes Operations at Manufacturing Unit in South Sikkim, India MT
Alembic Pharmaceuticals' Consolidated Net Profit Jumps in Fiscal Q3; EPS Tops Estimates MT
Alembic Pharmaceuticals' Consolidated Profit Climbs in Fiscal Q3, EPS Beats Estimates MT
Transcript : Alembic Pharmaceuticals Limited, Q3 2024 Earnings Call, Feb 05, 2024
India's Alembic Pharma beats Q3 profit view on strong domestic, US sales RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Alembic Pharmaceuticals Limited Announces Designation of Manuj Desai as Head - It as Senior Management Personnel CI
Alembic Pharmaceuticals Expects Operations at Sikkim, India Units to Be Restores in Two Months MT
Alembic Pharmaceuticals Extends Corporate Guarantee to US-Based Arm to Secure Credit MT
Alembic Pharmaceuticals Receives Various Us Food & Drug Administration Product Approvals CI
Alembic Pharmaceuticals Limited Cessation of Mr. Prerepa Sreenivasa Rao as Senior Management Personnel CI
Alembic Pharmaceuticals Limited Appoints Pradeep Chakravarty as Head - Global Quality CI
Alembic Pharmaceuticals Limited Announces Management Changes CI
Alembic Pharmaceuticals Logs Slightly Higher Consolidated Profit in Fiscal Q2; EPS Misses Estimates MT
Transcript : Alembic Pharmaceuticals Limited, Q2 2024 Earnings Call, Nov 07, 2023
India's Alembic Pharma Q2 profit roughly in-line with estimates RE
Alembic Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Alembic Pharmaceuticals Says Operations at South Sikkim Plant Disrupted by Flash Floods MT
Alembic Pharmaceuticals Limited Announces Disruption of Manufacturing Operations at Namthang, South Sikkim CI
Alembic Pharmaceuticals Limited Announces Management Changes CI
Chart Alembic Pharmaceuticals Limited
More charts
Alembic Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients (API). It delivers a diverse and expanding range of generics across chronic segments. Its therapies include Dermatology, Anti-Infective, Cold & Cough, Gastrology, Cardiology, Anti-Diabetic, Ophthalmology, Nephro/Uro, Animal Health, Orthopaedic and Gynaecology. Products under International Generics are manufactured across its facilities in Panelav, Karkhadi and Jarod in Gujarat. It has research and development facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (United States). Its APIs are manufactured at its three plants in Panelav and Karkhadi in Gujarat. The manufacturing facility in Sikkim is for manufacturing its India Formulations. Its subsidiaries include Alembic Pharmaceuticals Inc., Alembic Global Holding SA and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
984.8 INR
Average target price
901.1 INR
Spread / Average Target
-8.50%
Consensus